{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:02:21Z","timestamp":1793444541748,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtha.2024.05.026","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:07:45Z","timestamp":1718856465000},"page":"2629-2652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7093","authenticated-orcid":false,"given":"Suely M.","family":"Rezende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-6880","authenticated-orcid":false,"given":"Ignacio","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-3485","authenticated-orcid":false,"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-4277","authenticated-orcid":false,"given":"Omolade","family":"Awodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-2336","authenticated-orcid":false,"given":"Ana","family":"Boban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-7243","authenticated-orcid":false,"given":"Julie A.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-4122","authenticated-orcid":false,"given":"Samantha C.","family":"Gouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-7939","authenticated-orcid":false,"given":"Michael","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-9910","authenticated-orcid":false,"given":"Paula","family":"Nahuelhual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-5328","authenticated-orcid":false,"given":"Niamh","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-297X","authenticated-orcid":false,"given":"Renu","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-7061","authenticated-orcid":false,"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7496","authenticated-orcid":false,"given":"Frits R.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.05.026_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.026_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib5","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.026_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtha.2023.09.029","article-title":"Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease","volume":"22","author":"Verhagen","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib8","first-page":"635","article-title":"Molecular genotyping of the Italian cohort of patients with hemophilia B","volume":"90","author":"Belvini","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.026_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.026_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1988.03720010043038","article-title":"Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors","volume":"259","author":"Ewing","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.05.026_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00043426-199701000-00003","article-title":"Factor IX inhibitors and anaphylaxis in hemophilia B","volume":"19","author":"Warrier","year":"1997","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.05.026_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtha.2024.05.026_bib17","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.jtha.2024.05.026_bib18","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.026_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.05.026_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtha.2024.05.026_bib21","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2024.05.026_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jth.12828","article-title":"Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)","volume":"13","author":"Kavakli","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"Manco-Johnson","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A\u00a0randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - a success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib26","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib27","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib29","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib31","article-title":"Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B","volume":"8","author":"Olasupo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2024.05.026_bib32","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children","volume":"25","author":"Chozie","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib34","year":"2023","journal-title":"International Quality Plasma Program (IQPP)"},{"key":"10.1016\/j.jtha.2024.05.026_bib36","year":"2024","journal-title":"Blood guidances"},{"key":"10.1016\/j.jtha.2024.05.026_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2023.2247160","article-title":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study","volume":"16","author":"Sidonio","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.05.026_bib38","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.jtha.2023.07.030","article-title":"The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: Pathfinder6 end-of-trial results","volume":"21","author":"Kenet","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib39","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.026_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102265","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 previously untreated patients from Europe and Canada","volume":"7","author":"Fischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","article-title":"Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery","volume":"110","author":"Batorova","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.026_bib42","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/hae.14219","article-title":"Results of a randomized phase III\/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery","volume":"27","author":"Pabinger","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.026_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/hae.14470","article-title":"Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?","volume":"28","author":"Holstein","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1365-2516.2010.02329.x","article-title":"Surgery in patients with haemophilia and high responding inhibitors: Izmir experience","volume":"16","author":"Balkan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib47","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2516.2011.02504.x","article-title":"Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature","volume":"17","author":"Caviglia","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.05.026_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2516.2004.00938.x","article-title":"Surgery in haemophilic patients with inhibitor: 20 years of experience","volume":"10","author":"Quintana-Molina","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2516.2010.02223.x","article-title":"Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience","volume":"16","author":"Rodriguez-Merchan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib50","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.026_bib51","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/s-0043-1777766","article-title":"Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia A with factor VIII inhibitors","volume":"8","author":"Castaman","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2024.05.026_bib52","series-title":"Product monograph including patient medication information","year":"2023"},{"key":"10.1016\/j.jtha.2024.05.026_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez-Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib56","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/trf.13016","article-title":"EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France","volume":"55","author":"Polack","year":"2015","journal-title":"Transfusion"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.05.026_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/hae.13008","article-title":"NHF-McMaster guideline on care models for haemophilia management","volume":"22","author":"Pai","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.05.026_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/hae.13000","article-title":"Care models in the management of haemophilia: a systematic review","volume":"22","author":"Yeung","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib59","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jth.12708","article-title":"Guidance, guidelines, and communications","volume":"12","author":"Douketis","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib60","first-page":"691","article-title":"Modern treatment of haemophilia","volume":"73","author":"Berntorp","year":"1995","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jtha.2024.05.026_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.jtha.2024.05.026_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0609.1976.tb01115.x","article-title":"Evaluation of prophylactic replacement therapy in haemophilia B","volume":"16","author":"Morfini","year":"1976","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.jtha.2024.05.026_bib63","first-page":"457","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtha.2024.05.026_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2516.2004.00952.x","article-title":"Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden","volume":"10","author":"Carlsson","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1365-2516.1999.00325.x","article-title":"Economic aspects of haemophilia care","volume":"5","author":"Aldedort","year":"1999","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.026_bib66","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0029-1245105","article-title":"The multifactorial etiology of inhibitor development in hemophilia: genetics and environment","volume":"35","author":"Gouw","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.05.026_bib67","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A\u00a0new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH","volume":"19","author":"van Galen","year":"2021","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:54:37Z","timestamp":1724378077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1538783624003180"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.026","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}